Limb girdle muscular dystrophy is not a single disease. It is a group of inherited muscle disorders that share one pattern: weakness that starts in the muscles closest to the trunk, around the shoulders and the hips, and spreads from there.
Key takeaways
- The term describes a distribution of weakness, not a single cause. Variants in more than 32 genes can produce it, at an estimated frequency of between 1 in 14,500 and 1 in 123,000 people.
- The naming changed in 2018. LGMD1 and LGMD2 numbering gave way to LGMD D for dominant forms and LGMD R for recessive forms, followed by a number and the affected protein. Older records still use the old labels.
- Genetic testing rather than biopsy is now the usual route to a precise subtype. That matters because cardiac and respiratory risk differ by gene, as does trial eligibility.
- ICD-10-CM codes the group at G71.03, with subcodes down to the affected protein. Neither the parent G71.0 nor the sarcoglycan subdivision G71.034 is billable on its own.
- Myostatin inhibition has been tested repeatedly in muscular dystrophy without producing functional benefit. Nothing in that class treats this condition.
What limb girdle muscular dystrophy is
The phrase describes where the weakness sits. The limb girdles are the shoulder and pelvic girdles, the rings of muscle anchoring the limbs to the trunk. When those proximal muscles waste while the hands, feet and face are relatively spared early on, that is the limb girdle pattern.
What it is not is a diagnosis of cause. Dozens of genes produce that pattern, and the proteins they encode do very different jobs: holding the muscle membrane together, repairing it after damage, clearing damaged proteins out, or adding sugar chains to structural proteins. Two people can share the same three words on a clinic letter and have different genes, different ages of onset and different organ involvement.
You will see it written both as limb girdle muscular dystrophy and as limb-girdle muscular dystrophy. The hyphen is a style choice; both spellings appear across MedlinePlus, the Muscular Dystrophy Association and the literature.
The symptoms families notice first
The early signs are about movement rather than pain. MedlinePlus Genetics describes an unusual gait, waddling or up on the balls of the feet, difficulty running, and needing to push up from a squat with the arms because the thighs cannot do it alone. Prolonged toe walking can enlarge the calf muscles.
As weakness progresses, the shoulder blades may stick out from the back, a sign called scapular winging. The lower back may curve inward, or the spine sideways into a scoliosis. Some people develop contractures restricting the hips, knees, ankles or elbows. Severity and age of onset vary widely, MedlinePlus notes, even within one family.
Two organ systems sit outside the visible weakness, and they are why a precise diagnosis is worth pursuing. Heart muscle weakening occurs in some subtypes, and breathing muscle weakness ranges from mild to severe. Which risk applies depends heavily on the gene.
How the subtypes are named, and why the old names persist
For decades the subtypes were numbered LGMD1A, LGMD1B and so on for dominant inheritance, and LGMD2A, LGMD2B for recessive, in the order they were mapped. That system ran out of letters and kept absorbing conditions that did not belong.
The 229th ENMC international workshop in 2018 reformed it. Subtypes are now written as LGMD, then D for dominant or R for recessive, then a number for the order of discovery, then the affected protein. LGMD2A became LGMD R1 calpain-3-related and LGMD2B became LGMD R2 dysferlin-related. The same gene can appear twice: CAPN3 causes both LGMD R1 and the dominant LGMD D4.
Two genes account for a large share of cases. CAPN3, encoding calpain-3, is described by MedlinePlus as the most common cause and by GeneReviews as calpainopathy. DYSF, encoding dysferlin, is another common cause, covered as dysferlinopathy, which can also present as a distal rather than girdle pattern.
The practical consequence is that a report from 2009 and one from 2026 may name the same thing differently. Neither is wrong. When comparing documents, match on the gene, not the LGMD number.
How limb-girdle muscular dystrophy is diagnosed
Creatine kinase, an enzyme that leaks from damaged muscle, is usually elevated and is often the first abnormal result. It points at muscle without naming the subtype.
Genetic testing is now the main route. Multi-gene panels and exome sequencing identify the causative variant directly, faster and less invasively than the older sequence of biopsy, protein staining and targeted sequencing. Muscle MRI reads which muscles are affected and in what pattern, because some subtypes have characteristic signatures. Biopsy still has a role when genetic results are inconclusive.
Genetic counselling belongs in this process, not after it. Recessive and dominant forms carry different implications for siblings, children and extended family, and a counsellor can explain testing options for relatives and family planning.
ICD-10 codes for limb girdle muscular dystrophy
ICD-10-CM places the muscular dystrophy family under category G71.0. The parent is not billable alone, so a claim has to reach the subtype level.
| Code | Descriptor | Note |
|---|---|---|
| G71.0 | Muscular dystrophy | Parent. Not billable on its own |
| G71.00 | Muscular dystrophy, unspecified | The billable option when the type is not documented |
| G71.01 | Duchenne or Becker muscular dystrophy | |
| G71.02 | Facioscapulohumeral muscular dystrophy | |
| G71.03 | Limb girdle muscular dystrophies | Subdivided further, see below |
| G71.031 | Autosomal dominant limb girdle muscular dystrophy | |
| G71.032 | Autosomal recessive limb girdle muscular dystrophy due to calpain-3 dysfunction | |
| G71.033 | Limb girdle muscular dystrophy due to dysferlin dysfunction | |
| G71.034 | Due to sarcoglycan dysfunction | Subdivision. Not billable, needs a sixth character |
| G71.0340 | Sarcoglycan dysfunction, unspecified | |
| G71.0341 | Alpha sarcoglycan dysfunction | |
| G71.0342 | Beta sarcoglycan dysfunction | |
| G71.0349 | Other sarcoglycan dysfunction | |
| G71.035 | Limb girdle muscular dystrophy due to anoctamin-5 dysfunction | |
| G71.036 | Limb girdle muscular dystrophy due to fukutin related protein dysfunction | |
| G71.038 | Other limb girdle muscular dystrophy | |
| G71.039 | Limb girdle muscular dystrophy, unspecified | |
| G71.09 | Other specified muscular dystrophies | Where subtypes without their own code sit |
The structure mirrors the genetics, which is unusual for ICD-10 and useful here: a coder holding the molecular report can code to the protein, and G71.039 covers the case where none exists.
The sarcoglycan branch is where this trips people up. G71.034 looks like a code and is printed as one in older tables, but it is a subdivision requiring a sixth character, so a claim submitted with G71.034 rejects as invalid. It resolves to G71.0340 unspecified, G71.0341 alpha, G71.0342 beta and G71.0349 other. If your reference predates that expansion, this is the row to re-check.
Descriptors above are as returned by the NLM Clinical Table Search Service, and should still be checked against the current year's code set. Our muscular dystrophy ICD-10 reference covers the wider category.
What care looks like
No treatment reverses limb girdle muscular dystrophy. Care is supportive, organised around what the specific subtype tends to do.
That usually means physiotherapy and stretching to keep joints mobile and limit contractures, orthoses and mobility aids as they become useful, spine monitoring, and periodic respiratory assessment. Where the subtype carries cardiac risk, cardiology involvement becomes routine rather than a reaction to symptoms. Anaesthesia carries specific considerations in neuromuscular disease, worth raising before planned surgery.
Gene-transfer and gene-editing programmes have entered clinical trials for several subtypes. What is approved for a particular gene changes by year and country, and is a question for a neuromuscular specialist. That is another reason the genetic diagnosis matters: trial eligibility is written in gene names.
Where myostatin fits, and where it does not
This site is about myostatin, so it is worth being direct about what that field has delivered here.
Myostatin restrains muscle growth, and blocking it produces striking gains in animals, which made it an obvious idea for diseases that destroy muscle. The trials disappointed. In Duchenne, the most heavily studied indication, multiple programmes produced biological signals without changing how patients walked, climbed or stood; we go through each in myostatin inhibitors in Duchenne. ACE-031 was halted after safety signals, bimagrumab moved toward body composition, and apitegromab was developed in spinal muscular atrophy, a different disease.
None of that treats limb girdle muscular dystrophy, and nothing sold as a myostatin inhibitor supplement acts on this pathway in humans in any meaningful way; see myostatin inhibitor supplements and natural myostatin inhibitors. Families of newly diagnosed patients are a target market for that industry, which is why the evidence question deserves a straight answer.
Sources
- MedlinePlus Genetics: limb-girdle muscular dystrophy
- Straub et al, 229th ENMC international workshop: limb girdle muscular dystrophies, nomenclature and reformed classification
- GeneReviews: Calpainopathy
- GeneReviews: Dysferlinopathy
- Muscular Dystrophy Association: limb-girdle muscular dystrophy
- NLM Clinical Table Search Service, ICD-10-CM
Frequently asked questions
Is limb girdle muscular dystrophy the same as limb-girdle muscular dystrophy?
Yes. The hyphen is a spelling convention, and both forms appear in reputable sources including MedlinePlus and the Muscular Dystrophy Association. There is no clinical difference.
What is the ICD-10 code for limb girdle muscular dystrophy?
The group sits at G71.03 and is subdivided by protein: G71.031 autosomal dominant, G71.032 calpain-3, G71.033 dysferlin, G71.035 anoctamin-5, G71.036 fukutin related protein, G71.038 other, G71.039 unspecified. Sarcoglycan is the exception, needing a sixth character: G71.0340 unspecified, G71.0341 alpha, G71.0342 beta, G71.0349 other. Neither G71.0 nor G71.034 is billable.
Does it affect the heart?
In some subtypes, yes. MedlinePlus notes that weakening of the heart muscle occurs in some people with the condition, and the risk depends heavily on which gene is involved. That is one reason a precise genetic diagnosis is worth having: it tells the care team whether cardiac surveillance belongs in routine follow-up.
How is it different from Duchenne muscular dystrophy?
Duchenne is caused by variants in one X-linked gene, DMD, with a childhood onset. The limb girdle group covers more than 32 genes, both inheritance patterns, and a wider range of onset ages. They code separately, at G71.01 and G71.03.
Can supplements or exercise slow the progression?
Physiotherapy is part of standard supportive care, but the type and intensity are individual and set by the neuromuscular team, because inappropriate loading can be counterproductive in some muscle diseases. No supplement has been shown to alter the course, and products sold as myostatin inhibitors have no human evidence behind those claims.
This article is for educational purposes only and is not medical advice. It describes what published clinical sources say about limb girdle muscular dystrophy and does not recommend or discourage any treatment. Diagnosis, genetic testing, monitoring and treatment decisions belong with a qualified neuromuscular specialist and, where relevant, a genetic counsellor.